Bruton tyrosine kinase inhibitors (BTKi) represent a promising strategy to limit disability accumulation in multiple sclerosis (MS). Results from the HERCULES trial1 showed that tolebrutinib, a brain-penetrant BTKi, reduced by 31% the risk of disability progression in non-relapsing secondary progressive MS patients, with a good safety profile. Tolebrutininb may represent a major advance for this MS population with no treatment currently approved.
Tolebrutinib for non-relapsing secondary progressive multiple sclerosis: a critical therapeutic gap / Rocca, M. A.; Preziosa, P.; Filippi, M.. - In: MED. - ISSN 2666-6340. - 6:7(2025). [10.1016/j.medj.2025.100751]
Tolebrutinib for non-relapsing secondary progressive multiple sclerosis: a critical therapeutic gap
Rocca M. A.
Primo
;Preziosa P.Secondo
;Filippi M.Ultimo
2025-01-01
Abstract
Bruton tyrosine kinase inhibitors (BTKi) represent a promising strategy to limit disability accumulation in multiple sclerosis (MS). Results from the HERCULES trial1 showed that tolebrutinib, a brain-penetrant BTKi, reduced by 31% the risk of disability progression in non-relapsing secondary progressive MS patients, with a good safety profile. Tolebrutininb may represent a major advance for this MS population with no treatment currently approved.| File | Dimensione | Formato | |
|---|---|---|---|
|
MED 6_100751.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
1.46 MB
Formato
Adobe PDF
|
1.46 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
